P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847476.69621.cd |
| _version_ | 1797287932685451264 |
|---|---|
| author | F. J. Hernandez-Ilizaliturri J. Kuruvilla B. A. Christian I. W. Flinn S. E. Assouline M. L. Ulrickson D. J. Landsburg M. Stuart H. Lowman N. Levin D. Maetzel N. N. Viller A. MacLaren |
| author_facet | F. J. Hernandez-Ilizaliturri J. Kuruvilla B. A. Christian I. W. Flinn S. E. Assouline M. L. Ulrickson D. J. Landsburg M. Stuart H. Lowman N. Levin D. Maetzel N. N. Viller A. MacLaren |
| author_sort | F. J. Hernandez-Ilizaliturri |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:58Z |
| format | Article |
| id | doaj.art-da6d30c2b49f4c2c96a820d37727e01c |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:58Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-da6d30c2b49f4c2c96a820d37727e01c2024-03-02T03:51:55ZengWileyHemaSphere2572-92412022-06-0161039104010.1097/01.HS9.0000847476.69621.cd202206003-01039P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)F. J. Hernandez-Ilizaliturri0J. Kuruvilla1B. A. Christian2I. W. Flinn3S. E. Assouline4M. L. Ulrickson5D. J. Landsburg6M. Stuart7H. Lowman8N. Levin9D. Maetzel10N. N. Viller11A. MacLaren121 Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, United States of America2 The Princess Margaret Hospital, Toronto, ON, Canada3 The Ohio State University, Columbus, OH4 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States of America5 Division of Hematology, Sir Mortimer B. Davis-Jewish General Hospital, Department of Oncology, McGill University, Montreal, QC, Canada6 Banner MD Anderson Cancer Center, Gilbert, AZ7 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA8 Triphase Accelerator, La Jolla, CA, United States of America8 Triphase Accelerator, La Jolla, CA, United States of America8 Triphase Accelerator, La Jolla, CA, United States of America9 Triphase Accelerator, Toronto, ON, Canada9 Triphase Accelerator, Toronto, ON, Canada8 Triphase Accelerator, La Jolla, CA, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000847476.69621.cd |
| spellingShingle | F. J. Hernandez-Ilizaliturri J. Kuruvilla B. A. Christian I. W. Flinn S. E. Assouline M. L. Ulrickson D. J. Landsburg M. Stuart H. Lowman N. Levin D. Maetzel N. N. Viller A. MacLaren P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) HemaSphere |
| title | P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) |
| title_full | P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) |
| title_fullStr | P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) |
| title_full_unstemmed | P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) |
| title_short | P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) |
| title_sort | p1152 results from a phase i pharmacokinetic pk and safety study of trph 222 a novel cd22 targeting antibody drug conjugate in patients with relapsed refractory b cell non hodgkin lymphoma r r nhl |
| url | http://journals.lww.com/10.1097/01.HS9.0000847476.69621.cd |
| work_keys_str_mv | AT fjhernandezilizaliturri p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT jkuruvilla p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT bachristian p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT iwflinn p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT seassouline p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT mlulrickson p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT djlandsburg p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT mstuart p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT hlowman p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT nlevin p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT dmaetzel p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT nnviller p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl AT amaclaren p1152resultsfromaphaseipharmacokineticpkandsafetystudyoftrph222anovelcd22targetingantibodydrugconjugateinpatientswithrelapsedrefractorybcellnonhodgkinlymphomarrnhl |